Vilija N. Avizonis
Expertise in
10
conditions

Dr. Vilija N. Avizonis

Radiation Oncology
Imed Physicians
5121 S Cottonwood St, 
Murray, UT 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
10
conditions
Imed Physicians
5121 S Cottonwood St, 
Murray, UT 

Overview

Vilija Avizonis, MD is a radiation oncologist at Intermountain Health’s Utah Valley Clinic – Radiation Oncology in Provo, Utah. She supports patients across the Wasatch Front at various Intermountain facilities, using radiation therapy to treat cancer. Her practice is limited to radiation oncology treatments for cancer patients.Growing up in New Mexico, Dr. Avizonis graduated from the University of New Mexico with a bachelor’s degree in chemistry, she then received her MD degree at the University of New Mexico School of Medicine. Her internship, then residency in Radiation Oncology at LDS Hospital in Salt Lake City, were followed by fellowship in Head and Neck Radiation Therapy. She joined Radiation Oncology at LDS Hospital in 1992 and has loved caring for her patients at Intermountain.In her spare time, she spends time with her husband and dogs, hiking, snowshoeing, skiing and doing anything outdoors.

Dr. Avizonis is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Thymic Epithelial Tumor, Pleuropulmonary Blastoma, and Tongue Cancer.

Dr. Avizonis is board certified in American Board Of Radiology. She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 7 clinical trials. Dr. Avizonis is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in UT

Board Certifications

American Board Of Radiology

Hospital Affiliations

Intermountain Medical Center

Languages Spoken

English
Lithuanian

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Imed Physicians
5121 S Cottonwood St, Murray, UT 84107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
View 6 Less Clinical Trials

6 Total Publications

Impact of Consensus Guidelines, Clinical Trials, and COVID-19 on Fractionation Practices for Node-negative Intact Breast Cancer.
Impact of Consensus Guidelines, Clinical Trials, and COVID-19 on Fractionation Practices for Node-negative Intact Breast Cancer.
Journal: American journal of clinical oncology
Published: February 04, 2025
Similar Doctors
Expertise in
10
conditions
Dr. David K. Gaffney
Radiation Oncology
Expertise in
10
conditions
Dr. David K. Gaffney
Radiation Oncology
Referral may be required

Radiation Oncology - Sugarhouse

1280 E Stringham Ave, 
Salt Lake City, UT 
 (4.7 miles away)
801-581-2396
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Gaffney is a Radiation Oncologist practicing medicine in Salt Lake City, Utah. Dr. Gaffney is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Endometrial Cancer, Vulvar Cancer, and Breast Cancer. Dr. Gaffney is board certified in American Board Of Radiology. Dr. Gaffney is currently accepting new patients.

Expertise in
6
conditions
Dr. Jonathan D. Tward
Radiation Oncology
Expertise in
6
conditions
Dr. Jonathan D. Tward
Radiation Oncology
Referral may be required

Radiation Oncology - Sugarhouse

1280 E Stringham Ave, 
Salt Lake City, UT 
 (4.7 miles away)
801-581-2396
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Tward is a Radiation Oncologist practicing medicine in Salt Lake City, Utah. Dr. Tward is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, Prostatectomy, and Reconstructive Urology Surgery. Dr. Tward is board certified in American Board Of Radiology. Dr. Tward is currently accepting new patients.

Expertise in
8
conditions
Dr. Dennis C. Shrieve
Radiation Oncology
Expertise in
8
conditions
Dr. Dennis C. Shrieve
Radiation Oncology
Referral may be required

Radiation Oncology - Sugarhouse

1280 E Stringham Ave, 
Salt Lake City, UT 
 (4.7 miles away)
801-581-2396
Languages Spoken:
English
Accepting New Patients

Dennis Shrieve is a Radiation Oncologist practicing medicine in Salt Lake City, Utah. Dr. Shrieve is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Meningioma, Radiation Induced Meningioma, Gliosarcoma, Prostatectomy, and Microvascular Decompression. Dr. Shrieve is board certified in American Board Of Radiology. Dr. Shrieve is currently accepting new patients.

Frequently Asked Questions about Dr. Vilija N. Avizonis

How do I make an appointment with Dr. Vilija N. Avizonis?

You can book an appointment with Dr. Vilija N. Avizonis by calling their office at 801-507-3380. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vilija N. Avizonis a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vilija N. Avizonis is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vilija N. Avizonis specialize in?

While Dr. Vilija N. Avizonis is a Radiation Oncology, they have specific expertise in Breast Cancer, Thymic Epithelial Tumor, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Vilija N. Avizonis participate in research or clinical trials?

Yes. Dr. Vilija N. Avizonis has published 6 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Vilija N. Avizonis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vilija N. Avizonis accept my insurance?

Dr. Vilija N. Avizonis accepts most major insurance plans, including Aetna and BridgeSpan. We recommend calling the office directly at 801-507-3380 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Avizonis's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 44 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile